Covid UK: One in 25 people hospitalised since December WERE vaccinated, says SAGE

One in 25 Britons hospitalised with Covid since December were vaccinated, No10’s scientific advisers have found. 

Analysis by SAGE shows 1,800 out of 43,000 patients admitted with the virus since December 8 had received at least one dose of either Pfizer or AstraZeneca’s jab.  

The vast majority caught the coronavirus shortly before their appointment or in the fortnight afterwards, before immunity had kicked in. 

Researchers who carried out the study reiterated that the findings in no way should be viewed as proof that the vaccines do not work as well as hoped.

Instead, they believe people had taken unnecessary risks after getting their vaccine, or had caught the virus while travelling to and from vaccination centres.    

In a meeting on March 12, SAGE called for better Government communication about how long it takes for the jab to work – normally around a fortnight or more. 

About 300 of the patients were hospitalised 14 days after their first dose, with SAGE highlighting that ‘no vaccine is 100 per cent effective’. 

They were mostly over-80s, who are the most vulnerable to Covid and who struggle most to fight off the infection.

The expert group said going forward it will be analysing whether any of the cases are linked to other Covid variants feared to make vaccines less effective.

Government analysis has shown both Pfizer and AstraZeneca’s vaccines to be more than 90 per cent effective at reducing deaths and hospitalisations after both doses.

One in 25 Britons hospitalised with Covid since December had been vaccinated, the Government’s Scientific Advisory Group for Emergencies revealed today. The number of Covid hospital admissions among vaccinated people is shown in blue, versus non-vaccinated in red

Analysis by SAGE shows 1,800 out of 43,000 patients admitted with the virus since December 8 had received at least one dose of either Pfizer or AstraZeneca's jabs. The graphs highlight how just a fraction of overall admissions are among jabbed people

Analysis by SAGE shows 1,800 out of 43,000 patients admitted with the virus since December 8 had received at least one dose of either Pfizer or AstraZeneca’s jabs. The graphs highlight how just a fraction of overall admissions are among jabbed people

The vast majority of hospital patients in the past few months caught the virus shortly before their appointment or in the few days afterwards, before immunity had kicked in

The vast majority of hospital patients in the past few months caught the virus shortly before their appointment or in the few days afterwards, before immunity had kicked in

SAGE was able to work this by working backwards from date of admission. The incubation period of the virus is at least five days

SAGE was able to work this by working backwards from date of admission. The incubation period of the virus is at least five days

Efficacy is about 85 and 80 per cent twelve weeks after the first injection, and they prevent about 60 per cent of people from spreading the disease. 

The new paper, published today as part of the latest tranche of studies used by SAGE to advise ministers, looked at a total of 42,788 Covid hospital patients up to March 5.

Of those who fell ill after vaccination, the average time between getting their jab and being admitted to hospital was five days.

Given it usually takes five days after infection to fall ill with Covid, it suggests most had become infected shortly before or around the time they got their jab.

SAGE said it believed many people would have taken unnecessary risks after getting the vaccine, by presuming they were protected.

But they accepted many vulnerable people may have inadvertently been exposed travelling to and from their appointment.

Some vaccinated patients were also admitted for non-coronavirus reasons and were asymptomatic but later identified as PCR positive. 

Writing in the study, the experts said: ‘Elderly and vulnerable people who had been shielding, may have inadvertently been exposed and infected either through the end-to-end process of vaccination, or shortly after vaccination through behavioural changes where they wrongly assume they are immune.’

The tiny number of people admitted with the virus more than two weeks after being vaccinated were over the age of 80.

People in this age bracket are the most vulnerable to Covid and are among the least likely to be able to mount an immune response against it.

Minutes from its 83rd meeting on March 11 show SAGE said: ‘The observation that a significant number of people developing symptoms within a few days of a first dose may suggest some behaviour change following vaccination (and before immunity has developed). 

‘It is important therefore that communications around vaccination reinforce the need for safe behaviours to be maintained.

‘It may also be the case that some infections occur during the end-to-end process of vaccination (i.e. including journeys to and from vaccination). 

‘Many of those included in the study would have been vaccinated at a time when community prevalence was very high. 

‘Although the Covid vaccines in use in the UK are highly effective, no vaccine is 100 per cent effective, and some people will be hospitalised even after completing their full vaccination schedule (high confidence).

‘It will be particularly important to monitor the prevalence of different variants present in this group by sequencing to understand any potential immune escape.’

Does Britain have enough vaccine supplies for people’s second doses? France threatens supply of Pfizer jabs from EU and delays of AstraZeneca from India could halt roll-out for even LONGER 

Britain’s supply of second vaccine doses is heading into troubled waters as deliveries of both Pfizer and AstraZeneca’s jabs are in danger of being stopped by foreign governments. 

India has banned exports of the AstraZeneca jab being made at the Serum Institute so it can use them for its own citizens, delaying a shipment of five million doses bound for the UK.

And EU officials are poised to stop shipments of Pfizer vaccines – which the UK needs to complete second doses for around 10million people by mid-June. 

Insiders say AstraZeneca’s supplies can be made entirely in the UK and the five million-dose boost from India was not critical to meeting government targets, meaning the delivery from India may be a disappointment rather than a crisis.

But all of the country’s Pfizer doses are made in factories in Europe – the firm and its partner BioNTech have major facilities in Belgium and Germany – and international shipping is vital to make sure people get their second doses.

More than 12million Pfizer doses have already been sent to Britain and the NHS needs at least the same number again by June to make sure everyone gets their booster jab within three months, as promised by the government.

Medics have already stopped giving out the vaccine to first-time patients so it can prioritise all the Pfizer supplies – which are now in danger of grinding to a halt – for existing patients’ second doses.  

No10 today insisted that Britain is still on track to hit its vaccination targets even in spite of supply troubles. 

A senior government source said: ‘We are confident in vaccine targets, offering first doses to all over-50s by April 15 and all adults by July 31, as well as second doses.’ There are understood to be around 12million doses due to be delivered in April.  

But now there is a prospect of open-ended delays to the jabs with political tensions rising and other countries facing yet more increases in infections.

India is in the grip of a second wave and holding vaccines from the Serum Institute so it can immunise its own one billion citizens, and cases are surging again in parts of Western Europe, where the rollout has been less successful than in Britain. As a result, politicians are trying to cling to vaccine supplies to use them on their own unprotected citizens.

And Moderna’s vaccine, which is expected to be the third and latest addition to the UK rollout from next week, will have to be imported from Europe, too, although it is manufactured in Switzerland which isn’t part of the EU.